Avicanna Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Avicanna şirketinin toplam hissedar öz sermayesi CA$9.2M ve toplam borcu CA$84.9K olup, bu da borç-öz sermaye oranını 0.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$20.5M ve CA$11.3M dir.

Anahtar bilgiler

0.9%

Borç/özkaynak oranı

CA$84.92k

Borç

Faiz karşılama oranı	n/a
Nakit	CA$812.07k
Eşitlik	CA$9.19m
Toplam yükümlülükler	CA$11.28m
Toplam varlıklar	CA$20.47m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0NN 'nin kısa vadeli varlıkları ( CA$8.0M ) kısa vadeli yükümlülüklerini ( CA$9.7M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 0NN şirketinin kısa vadeli varlıkları ( CA$8.0M ) uzun vadeli yükümlülüklerini ( CA$1.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0NN şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 0NN 'nin borç/öz sermaye oranı son 5 yılda 9.4% seviyesinden 0.9% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0NN son raporlanan serbest nakit akışına göre 3 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: 0NN serbest nakit akışı tahminlerine göre 2 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Avicanna Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Inc. announced that it has received CAD 0.80001 million in funding

Avicanna Inc. announced that it has received CAD 1.986208 million in funding

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought €169k worth of stock

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Insider recently bought €90k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought €388k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.085 loss in 1Q 2021)

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Full year 2021 earnings released: CA$0.41 loss per share (vs CA$1.12 loss in FY 2020)

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin